Eltrombopag Global Buyers List: Comprehensive Guide for Pharmaceutical Suppliers
Eltrombopag, marketed under brand names including Promacta (in the United States) and Revolade (internationally), is an oral thrombopoietin receptor agonist used to treat thrombocytopenia in patients with chronic immune thrombocytopenia (ITP) and severe aplastic anemia. As a highly valued pharmaceutical product with a global market projected to expand from USD 2.68 billion in 2025 to USD 4.22 billion by 2031, understanding the landscape of global buyers is essential for suppliers, manufacturers, and distributors seeking to expand their market presence.
This comprehensive guide provides pharmaceutical suppliers with actionable intelligence on Eltrombopag buyers worldwide, including key importers, distributors, and procurement channels across major markets.
Understanding the Eltrombopag Global Market
Market Overview and Growth Drivers
The Eltrombopag drugs market has demonstrated strong growth, with the market size reaching approximately USD 2.49–2.68 billion in 2025. Several factors drive this expansion:
- Rising prevalence of chronic immune thrombocytopenia, with incidence recorded at approximately 6.1 per 100,000 people
- Growing adoption of oral therapies over injectable alternatives
- Expanded regulatory approvals for pediatric use and first-line treatment settings
- Patent expirations enabling generic entry and broader market access
Key Market Regions
North America represents the largest market for Eltrombopag, followed by Europe and Asia-Pacific. Major importing countries include Russia, the United States, and various European nations. India dominates global exports, accounting for approximately 71–82% of Eltrombopag API exports.
Major Categories of Eltrombopag Global Buyers
1. Multinational Pharmaceutical Companies
The largest buyers of Eltrombopag include major pharmaceutical corporations that either manufacture finished dosage forms or distribute the product through global networks:
- Novartis Pharmaceuticals – The primary innovator company marketing Promacta and Revolade, with 2024 annual net sales of approximately USD 2.2 billion for these products. Novartis operates extensive procurement operations across Switzerland, the UK, and multiple global markets.
- Dr. Reddy‘s Laboratories – A major generic manufacturer with significant procurement and distribution operations across India, Brazil, Malaysia, and the UK.
- Teva Pharmaceutical Industries – A key player in generic Eltrombopag production and distribution.
- Aurobindo Pharma – An active manufacturer and buyer in the Eltrombopag supply chain.
- Hetero Drugs Ltd – Among the top importing companies and manufacturers.
2. Regional Pharmaceutical Distributors and Wholesalers
Regional distributors serve as critical intermediaries between manufacturers and end-users:
- Synergy Health Utrecht B.V. – Netherlands-based distributor with 41 recorded transactions involving Eltrombopag.
- Bluepharma Industria Farmaceut – Portugal-based company with 403 transactions and a high Active Value score of 75 in Eltrombopag-related trade.
- Sopharma S.R.L. – Bolivia-based distributor with 55 transactions.
- Cordium Pharmaceuticals Pvt Ltd – India-based exporter serving markets including Morocco, Kenya, Singapore, Australia, Germany, France, Canada, and Saudi Arabia.
3. Healthcare Institutions and Public Procurement Bodies
Government healthcare systems and hospital procurement trusts represent significant buyers:
- Belfast Health & Social Care Trust – UK public healthcare buyer procuring Revolade tablets.
- NHS (National Health Service, UK) – Operates national frameworks for Eltrombopag procurement, with suppliers including Dr. Reddy’s Laboratories and Novartis Pharmaceuticals.
- Various national regulatory agencies and hospital procurement departments worldwide.
4. API Importers and Raw Material Buyers
For suppliers of Eltrombopag Active Pharmaceutical Ingredients (API), key buyers include:
- MSN Laboratories Private Limited – Among the top importing companies.
- Watson Pharma Pvt Ltd – A leading importer of Eltrombopag API.
- Cipla Ltd – India-based pharmaceutical company with documented Eltrombopag procurement activities.
- Crest Remedies LLP – Active buyer of Eltrombopag Olamine API.
5. Finished Dosage Form Buyers
Buyers of Eltrombopag tablets (typically 25 mg, 50 mg, and 75 mg strengths) include:
- Evaric Pharmaceuticals Inc – US-based supplier with import activities.
- Delpher S.A.C. – Peru-based buyer with 56 transactions.
- Soliumpharma S.A.S. – Ecuador-based buyer with 50 transactions.
- Elea Peru S.A.C. – Peru-based buyer with 171 transactions.
Comprehensive Eltrombopag Buyers List by Region
North America
Europe
Latin America
Asia-Pacific
How to Identify and Connect with Eltrombopag Buyers
Leveraging Trade Data Platforms
Several platforms provide access to verified import-export data for identifying active Eltrombopag buyers:
- 52wmb.com – Offers comprehensive trade data with buyer profiles, transaction histories, and contact information
- TheTradeVision.com – Provides global trade data compiled from 180+ countries with detailed shipment records
- PharmaDB.ai – Lists 22 API manufacturers with regulatory credentials
- PharmaOffer.com – Provides API pricing and transaction intelligence
Utilizing Public Procurement Databases
Government procurement websites and tender platforms are valuable resources:
- Find a Tender Service (UK) – Lists NHS procurement frameworks
- Bidstats.uk – Publishes public sector procurement notices
- GlobalTenders.com – Aggregates pharmaceutical tenders worldwide
Engaging with Pharmaceutical Trade Shows and B2B Platforms
Industry events and B2B platforms facilitate direct buyer-seller connections:
- CPHI – Global pharmaceutical trade shows where Eltrombopag buyers and sellers connect
- Alibaba.com – Platform for sourcing Chinese manufacturers and connecting with international buyers
- PipelinePharma.com – Direct connection platform for pharmaceutical manufacturers and buyers
Key Considerations for Suppliers Targeting Eltrombopag Buyers
Regulatory Compliance
Eltrombopag is a prescription medication subject to strict regulatory oversight in all major markets. Suppliers must ensure:
- Product registration and authorization in the destination country
- Compliance with local pharmaceutical import requirements
- Proper documentation, including commercial invoices, certificates of analysis, and batch records
- Adherence to prescription and controlled substance regulations where applicable
Product Availability and Specifications
Buyers typically require specific product specifications:
- Available strengths: 25 mg, 50 mg, and 75 mg tablets
- Formulations: Film-coated tablets, with some markets offering suspension formulations
- Brand vs. Generic: Buyers may seek either branded (Promacta/Revolade) or generic (Eltrombopag Olamine) products
Patent and Intellectual Property Considerations
With primary patents on Eltrombopag expiring or already expired in the US and EU (approximately 2025-2026), generic entry has created new procurement opportunities. However, suppliers should verify patent status in each target market, as some jurisdictions may maintain composition patents. Generic versions have been approved, including by Annora Pharma in April 2024.
Pricing and Procurement Volume
Eltrombopag pricing varies significantly by market and volume:
- API median export price: Approximately USD 5,987 per kg
- Treatment costs: Continuous treatment with thrombopoietin receptor agonists averages approximately USD 162,253 in total healthcare costs
- Volume discounts: Bulk and recurring requirements typically qualify for preferential pricing
Emerging Market Opportunities
Several markets present growing opportunities for Eltrombopag suppliers:
- Africa: Markets including Morocco and Kenya are expanding their pharmaceutical procurement capabilities
- Southeast Asia: Singapore, Malaysia, and Indonesia show increasing demand
- Middle East: Saudi Arabia represents a growing market with authorized importers
- Latin America: Brazil, Peru, Colombia, and Ecuador demonstrate active trading volumes
AMNEAL PHARMACEUTICALS PRIVATE LIMITED
WATSON PHARMA PRIVATE LIMITED
ACTAVIS PHARMA DEVELOPMENT CENTRE PRIVATE LIMITED
NOVARTIS FARMACEUTICA SA DE CV
HEALTHCARE PHARMACEUTICALS LTD
JUAN DANIEL ZAPATA ZAPATA
NOVARTIS HEALTHCARE PRIVATE LIMITED
HIMMEL PHARMACEUTICALS PVT LIMITED
ТОО АБДИ ИБРАХИМ ГЛОБАЛ ФАРМ
CÔNG TY TNHH NOVARTIS VIỆT NAM
GENBIE SAS
VEEDA CLINICAL RESEARCH LIMITED
ELEA PERU S A C
GENERICS AFRICA LIMITED
AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED
AUROBINDO PHARMA LTD
KHAIRI S A
SYNTHON CHILE LIMITADA
ZYDUS LIFESCIENCES LIMITED
CIPLA LIMITED
C G DE HASETH CIA S A
DELPHER S A C
DR REDDY S LABORATORIES LTD
HETERO LABS LIMITED
MOLECULES ANALYTICAL LAB SOLUTIONS PRIVATE LIMITED
MSN LABORATORIES PRIVATE LIMITED
CLIANTHA RESEARCH LIMITED
EVEREST PHARMACEUTICALS LIMITED
GLOBAL MED FARMA S A C
INTERVEIN RESEARCH LABS PRIVATE LIMITED
RENATA PLC CHANGED FROM RENATA
VIMTA LABS LIMITED
DROGUERIA LABORATORIOS PHARMEX SAC
M S HELIX PHARMA PVT LTD
NATCO PHARMA LIMITED
NOVARTIS DE COL S A
SEVEN PHARMA CHILE SPA
SIGMA ALDRICH CHEMICALS PRIVATE LIMITED
ANNORA PHARMA PRIVATE LIMITED
BIOPLUS CARE PANAMA S A
NOVADOZ PHARMACEUTICALS LLC
PHARMASOL PRIVATE LTD
PT AMAROX PHARMA GLOBAL
SOPHARMA S R L
V M G PHARMA SOCIEDA ANOMIMA SA
VMG HEALTH CARE PRODUCTS S A
ASTOR ALLIANCE
CUNNINGHAM PHARMACEUTICALS PRIVATE LIMITED
GLENMARK PHARMACEUTICALS LIMITED
INCEPTA PHARMACEUTICALS LIMITED
JENPHAR BANGLADESH LIMITED CHANGED
LUPIN LIMITED
MANKIND PHARMA LIMITED
SOLIUMPHARMA S A S
SUN PHARMACEUTICAL INDUSTRIES LIMITED
ACCUTEST RESEARCH LABORATORIES INDIA PRIVATE LIMIT
ADVANCED CHEMICAL INDUSTRIES LTD
ADVANCED CHEMICAL INDUSTRIES PLC
BEACON PHARMACEUTICALS PLC
CUNNINGHAM PHARMACEUTICALS PVT LTD
CÔNG TY TNHH MTV NOVALAB
DRUGLAND CORPORATION
LAMBDA THERAPEUTIC RESEARCH LIMITED
PHARMACIL LIMITED
PROTEIN SA DE CV
SEVEN PHARMA SAC
SYNTHON MEXICO SA DE CV
TEXAS CANCER CENTRE LIMITED
ABDI IBRAHIM ILAC SANAYI VE TICARET ANONIM SIRKETI
ANALYS LAB PRIVATE LIMITED
ASKENY PERU S A C
BIOPLUS CARE SOCIEDAD ANONIMA
CÔNG TY CỔ PHẦN DƯỢC PHẨM VĨNH PHÚC
HELIX PHARMA PRIVATE LIMITED
JSC RAFARMA
LABORATORIOS BIOGENET SCC
M S MEDISURE LABORATORIES PAKISTAN PVT LTD
MSN LABS PERU S A C
NEDAH PHARMA LIMITED
NOBEL ILAC SANAYII VE TICARET ANONIM SIRKETI
O ZBEKISTON RESPUBLIKASI SOGLIQNI SAQLASH VAZIRLIGI HUZURIDAGI XARIDLAR MARKAZI DM
ONCOPHARM U LTD
PHARMASOL PVT LTD
RIPPLE PHARMACEUTICALS LIMITED
TABRANE HEALTHCARE PVT LTD
TOKYO CHEMICAL INDUSTRY INDIA PRIVATE LIMITED
ULSA TECH SA DE CV
2MG INCORPORATED
ACCUTEST RESEARCH LABORATORIES INDIA PRIVATE LIMITED
ACTIMUS BIOSCIENCES PRIVATE LIMITED
ALLIANZ BIOINNOVATION
AZIDUS LABORATORIES LIMITED
BIOORGANICS AND APPLIED MATERIALS PRIVATE LIMITED
CAJAEXPRESS COURIER S A
CÔNG TY TNHH DRP INTER
CÔNG TY TNHH SẢN XUẤT NAVIS VIỆT NAM
ECOCHEM SAS
ESKAYEF PHARMACEUTICALS LIMITED
GOLD TREE PHARMACEUTICALS LTD
HELIX PHARMA PVT LIMITED
KAIZEN PHARMACEUTICALS PVT LTD
KARDU PHARMA SAS
KWALITY PHARMACEUTICALS LIMITED
LABORATORIO ECZANE PHARMA S A
MEDISURE LABORATORIES PAKISTAN PVT LTD
MEGALABS BOLIVIA S R L
MERU DOCTORS PLAZA LIMITED
NEWGEN LANKA HEALTH CARE PVT LTD
OOO ASTOR ALLIANCE
ORIENTAL FARMACEUTICA INDUSTRIAL COMERCIAL E INMOBILIARIA SO
PHARMAFFILIATES PRIVATE LIMITED
POPULAR PHARMACEUTICALS PLC
RELATIONS INTERNATIONAL LIMITED
RELIUS PHARMA SRL
RENATA LTD CHANGE FROM PFIZER
SCORP MEDITECH LIMITED
SIGMA ALDRICH QUIMICA S DE RL DE CV
SRI KRISHNA PHARMACEUTICALS LIMITED
STATE PHARMACEUTICALS CORPORARION
ZETI PHARMACEUTICALS PHARMAZETI CIA LTDA
НИИ ГЕМАТОЛОГИЯ И ПК
ТОВ БУСТ ФАРМА 03022 КИЇВ В ВАСИЛЬКІВСЬКА Б 30
API INTERNATIONAL
APOTEX RESEARCH PRIVATE LIMITED
AUXILLA PHARMACEUTICALS AND RESEARCH LLP
BASIC BUSINESS CONSORTIUM
BIOBIZ INTERNATIONAL
CAPONEX LABS PRIVATE LIMITED
CASA FARMACEUTICA S A C
CLEARSYNTH LABS LIMITED
CORPORACION BENPHARMA S A C
CÔNG TY CỔ PHẦN DƯỢC PHẨM SAVI
CÔNG TY CỔ PHẦN ÁNH SÁNG CHÂU Á
CÔNG TY TNHH VẬT TƯ KHOA HỌC CÔNG NGHỆ T T
CÔNG TY TRÁCH NHIỆM HỮU HẠN SINH DƯỢC PHẨM HERA
DHL PAKISTAN PRIVATE LIMITED
DISTRIBUIDORA FARMANOVA SOCIEDAD ANONIMA
DROGUERIA SARO S A
EMCURE PHARMACEUTICALS LTD
ESJAY PHARMA PRIVATE LIMITED
EVERSANA LIFE SCIENCE SERVICES
GEODIS USA LLC
GLOBAL PHARMA Y LOGISTIC S A S
GLOBELA PHARMA PRIVATE LIMITED
GRAND CORPORATION PVT LTD
GRANULES INDIA LIMITED
J S LABS
LABORATORIOS SAVAL S A
M S ROTEX PHARMA PVT LIMITED
M S SCILIFE PHARMA PVT LTD
M S WNSFIELD PHARMACEUTICLS
MARK JOHN TAMAYO
MEDICEL S A
MEER ALAM
NIPPON EXPRESS USA INC
NOVARTIS ARGENTINA S A
OH INNOLEK
OPSONIN PHARMA LIMITED
PHARMAFFILIATES ANALYTICS AND SYNTHETICS PRIVATE L
PHARMARAW BANGLADESH PRB
PHARMASOL PRIVATE LIMITED
RC2 PHARMACEUTICAL S A S
REPRESENTACIONES CELMAR S A
SCILIFE PHARMA PRIVATE LIMITED
SCILIFE PHARMA PVT LTD
SEVEN PHARMA PANAMA
SHAROOQ PHARMACEUTICALS PRIVATE LIMITED
SIERRA S A
SIMSON PHARMA LIMITED
SITEC LABS LIMITED
STAR TRADING SOLUTIONS S A S
STATE INSTITUTION PURCHASING CENTER UNDER THE MINISTRY OF HEALTH OF THE REPUBLIC OF UZBEKISTAN
SURYA PHARMA LIMITED
SWISS NORTH GROUP S A
THE LABS S A S
TS CORPORATION
WINTHROP PHARMACEUTICALS DE COLOMBIA SA
ZISKA PHARMACEUTICALSLIMITED
ООО CHEMO LAB
ООО NOVOTEK
Conclusion
The global Eltrombopag buyer landscape is diverse, encompassing multinational pharmaceutical corporations, regional distributors, public healthcare institutions, and API importers. As the market continues its strong growth trajectory, suppliers who understand buyer segmentation, regulatory requirements, and effective engagement channels will be best positioned to capture opportunities.
Success in this market requires a strategic approach combining trade data intelligence, regulatory compliance, and targeted outreach to qualified buyers across key regions. By leveraging the resources and insights provided in this guide, pharmaceutical suppliers can navigate the global Eltrombopag market with confidence and build sustainable buyer relationships worldwide.
